# US 2025/0166254 A1 · Integrated medicament delivery device for use with continuous analyte sensor > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2025/0166254 A1 - Document ID: US20250166254A1 - Status: Published application - Kind: A1 - Application number: 19/028,394 - Filed: 2025-01-17 - Published: 2025-05-22 - Earliest claimed: 2007-06-08 - Assignees: DexCom, Inc. - Applicants: DexCom, Inc. - Inventors: Apurv Ullas Kamath; Richard C. Yang; Jacob S. Leach; Nelson Quintana - Web page: https://patentgrep.com/patent/US20250166254A1 ## CPC - G06T 11/26: Drawing of charts or graphs - A61B 5/0002: {Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network (endoradiosondes A61B5/07)} - A61B 5/14532: {for measuring glucose, e.g. by tissue impedance measurement} - A61B 5/14546: {for measuring analytes not otherwise provided for, e.g. ions, cytochromes} - A61B 5/14865: {invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors} - A61B 5/4839: {combined with drug delivery} - A61M 5/24: Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic - A61M 5/31525: {Dosing (burettes, pipettes B01L3/02)} - A61B 2560/0406: specially shaped apparatus housings - A61B 2560/0431: Portable apparatus, e.g. comprising a handle or case - A61B 2560/0443: Modular apparatus - A61M 5/003: {Kits for diabetics} - A61M 5/14244: {adapted to be carried by the patient, e.g. portable on the body} - A61M 5/1723: {using feedback of body parameters, e.g. blood sugar or pressure} - A61M 5/3129: {Syringe barrels (A61M5/3205, A61M5/50 take precedence)} - A61M 2205/3569: sublocal, e.g. between console and disposable - A61M 2205/505: Touch-screens; Virtual keyboard or keypads; Virtual buttons; Soft keys; Mouse touches - A61M 2209/086: Docking stations - G06T: IMAGE DATA PROCESSING OR GENERATION, IN GENERAL - A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D) - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} ## Abstract An integrated system for the monitoring and treating diabetes is provided, including an integrated receiver/hand-held medicament injection pen, including electronics, for use with a continuous glucose sensor. In some embodiments, the receiver is configured to receive continuous glucose sensor data, to calculate a medicament therapy (e.g., via the integrated system electronics) and to automatically set a bolus dose of the integrated hand-held medicament injection pen, whereby the user can manually inject the bolus dose of medicament into the host. In some embodiments, the integrated receiver and hand-held medicament injection pen are integrally formed, while in other embodiments they are detachably connected and communicated via mutually engaging electrical contacts and/or via wireless communication. ## Claims ### Claim 1 A method for managing diabetes, the method comprising: receiving continuous glucose sensor data from a continuous glucose sensor, wherein the continuous glucose sensor data comprises a plurality of glucose concentrations measured in an interstitial fluid of a host by the continuous glucose sensor; receiving a food intake input from a user interface, wherein the food intake input comprises an indication of consumption of food and/or drink by the host; calculating a bolus therapy recommendation, the bolus therapy recommendation comprising a meal insulin dose and an insulin dose adjustment, wherein: the meal insulin dose is calculated based on an evaluation of at least the food intake input to compensate for an expected rise in glucose concentration predicted to occur in a bodily fluid of the host from the consumption of food and/or drink by the host, the insulin dose adjustment is calculated based on an evaluation of at least the continuous glucose sensor data to correct a current glucose deviation and/or a predicted future glucose deviation, wherein: the current glucose deviation comprises a difference resulting from comparing one or more glucose concentrations measured in the interstitial fluid of the host with a target glucose concentration for the bodily fluid of the host, and the predicted future glucose deviation comprises a difference resulting from comparing one or more glucose concentrations predicted to occur in the interstitial fluid of the host and/or the bodily fluid of the host with the target glucose concentration for the bodily fluid of the host; validating the calculated bolus therapy recommendation by obtaining a therapy confirmation, the obtaining the therapy confirmation comprising: displaying the calculated bolus therapy recommendation on the user interface, and receiving a confirmation input from the user interface, wherein the confirmation input comprises an indication of acceptance of the displayed bolus therapy recommendation; and issuing an insulin delivery instruction to an insulin delivery device, wherein the insulin delivery instruction instructs the insulin delivery device to deliver insulin to the host according to the bolus therapy recommendation as validated by the obtained therapy confirmation. ### Claim 2 (depends on 1) The method of claim 1, wherein the insulin delivery device is an infusion pump. ### Claim 3 (depends on 2) The method of claim 2, wherein the method is performed by processing circuitry integrated into the infusion pump. ### Claim 4 (depends on 2) The method of claim 2, wherein the method is performed by a separate receiver device operably connected to the infusion pump. ### Claim 5 (depends on 1) The method of claim 1, wherein the food intake input comprises an amount of carbohydrates and/or calories that the host has consumed, is consuming, and/or anticipates consuming. ### Claim 6 (depends on 1) The method of claim 1, wherein validating the calculated bolus therapy recommendation further comprises modifying the calculated bolus therapy recommendation based on input from the user interface. ### Claim 7 (depends on 1) The method of claim 1, wherein the bodily fluid of the host comprises the interstitial fluid of the host. ### Claim 8 (depends on 1) The method of claim 1, wherein the bodily fluid of the host comprises blood of the host, and the plurality of glucose concentrations measured in the interstitial fluid of the host are converted to glucose concentrations in the blood of the host, and/or the one or more glucose concentrations predicted to occur in the blood of the host are predicted from the plurality of glucose concentrations measured in the interstitial fluid of the host. ### Claim 9 (depends on 1) The method of claim 1, wherein the continuous glucose sensor data is displayed by the user interface. ### Claim 10 (depends on 1) The method of claim 1, wherein the insulin dose adjustment is calculated to correct the current glucose deviation, and the current glucose deviation comprises the difference resulting from comparing: a trend comprising more than one glucose concentration measured in the interstitial fluid of the host, with the target glucose concentration. ### Claim 11 (depends on 1) The method of claim 1, wherein the meal insulin dose is calculated based on: an evaluation of the food intake input, and an input indicating exercise and/or illness. ### Claim 12 (depends on 1) The method of claim 1, wherein the insulin dose adjustment is calculated based on: an evaluation of the continuous glucose sensor data, and an input indicating exercise and/or illness. ### Claim 13 (depends on 1) The method of claim 1, wherein: the calculated bolus therapy recommendation comprises a single insulin dose, the single insulin dose comprises the meal insulin dose, and the insulin dose adjustment increases and/or decreases the meal insulin dose. ### Claim 14 (depends on 1) The method of claim 1, wherein the calculated bolus therapy recommendation comprises two or more separate insulin doses, and the two or more separate insulin doses comprise the meal insulin dose and the insulin dose adjustment. ### Claim 15 (depends on 1) The method of claim 1, wherein the meal insulin dose is a positive amount of insulin, the insulin dose adjustment is a negative amount of insulin, and the insulin delivery instruction comprises a sum of the positive meal insulin dose and the negative insulin dose adjustment. ### Claim 16 A diabetes management system, the system comprising: a receiver, the receiver comprising: an RF transceiver configured to receive continuous glucose sensor data from a continuous glucose sensor, the continuous glucose sensor data comprising a plurality of glucose concentrations measured in an interstitial fluid of a host by the continuous glucose sensor; a display configured to display a bolus therapy recommendation; a user interface configured to receive a food intake input and a confirmation input, the food intake input comprising an indication of consumption of food and/or drink by the host, and the confirmation input comprising an indication of acceptance of the bolus therapy recommendation displayed by the display; and a processor configured to calculate the bolus therapy recommendation, obtain a bolus therapy confirmation, and issue an insulin therapy instruction, wherein: the bolus therapy recommendation comprises a meal insulin dose and an insulin dose adjustment, the meal insulin dose is calculated, by the processor, based on an evaluation of at least the food intake input to compensate for an expected rise in glucose concentration predicted to occur in a bodily fluid of the host from the indicated consumption of food and/or drink by the host, and the insulin dose adjustment is calculated, by the processor, based on an evaluation of at least the continuous glucose sensor data to correct a current glucose deviation and/or a predicted future glucose deviation, wherein: the current glucose deviation comprises a difference resulting from comparing one or more glucose concentrations measured in the interstitial fluid of the host with a target glucose concentration for the bodily fluid of the host, and the predicted future glucose deviation comprises a difference resulting from comparing one or more glucose concentrations predicted to occur in the interstitial fluid of the host and/or the bodily fluid of the host with the target glucose concentration for the bodily fluid of the host; the obtaining the bolus therapy confirmation comprises receiving a confirmation input that validates the bolus therapy recommendation, wherein: the bolus therapy recommendation is displayed on the display, and the confirmation input is received from the user interface; and the insulin therapy instruction comprises the bolus therapy recommendation once validated by the obtained bolus therapy confirmation; and an insulin infusion pump operably connected to the receiver, wherein the insulin infusion pump receives the insulin therapy instruction from the operatively connected receiver and delivers insulin to the host according to the insulin therapy instruction. ### Claim 17 (depends on 16) The system of claim 16, wherein the receiver comprises circuitry integrated with the insulin infusion pump. ### Claim 18 (depends on 16) The system of claim 16, wherein the bodily fluid of the host comprises the interstitial fluid of the host. ### Claim 19 (depends on 16) The system of claim 16, wherein the bodily fluid of the host comprises blood of the host, and the plurality of glucose concentrations measured in the interstitial fluid of the host are converted to glucose concentrations in the blood of the host, and/or the one or more glucose concentrations predicted to occur in the blood of the host are predicted from the plurality of glucose concentrations measured in the interstitial fluid of the host. ### Claim 20 (depends on 16) The system of claim 16, wherein the user interface is integrally formed with the display, and wherein the integrally formed user interface and display comprises an LED screen.